BioSpace News Archive

Moderna Inc., Moderna , Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Shannon Thyme Klinger will join the Company as Chief Legal Officer, effective June 1, 2021. She will serve on Moderna’s Executive Committee and as Corporate Secretary and report to Chief Executive Officer Stéphane Bancel.

Intersect ENT®, Inc., a global ear, nose and throat medical technology leader dedicated to transforming patient care, announced that the Centers for Medicare and Medicaid Services published an average selling price for the Company’s SINUVA sinus implant, providing predictability, transparency, and confidence of reimbursement for providers and payers going forward.

Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced that it has entered into an out-licensing and product discovery agreement with Kermode Biotechnologies, Inc. Kermode works on vaccines and mAbs for zoonotic viruses, which are animal viruses that have the ability to infect humans.

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), today announced that Alan Joslyn, Ph.D., President and Chief Executive Officer of Oragenics, will participate in two virtual investment conferences during the month of March, as follows: The H.C. Wainwright Global Life Sciences Virtual Conference with one-on-one meetings being held March 9-10, 2021

Gritstone Oncology, Inc., a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, announced two promotions within its leadership team.

Vlad Hogenhuis, M.D., MBA, and Nerissa C. Kreher, M.D., M.S., MBA, to join board of directors as Rezolute advances lead candidate, RZ358, in congenital hyperinsulinism through late-stage clinical trials

Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced the opening of the first Pneusomnia clinic,

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company delivered a presentation on its SARS-CoV-2 3CL pro inhibitor candidate, ALG-097111, at the 28 th Conference on Retroviruses and Opportunistic Infections, being held virtually March 6 to March 10, 2021,

Dr. Paul Walker will remain on the Board of Directors focusing on the seamless transition of management and on ensuring continuity of the Tigris Trial

Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that the U.S. Food and Drug Administration (“FDA”) has granted orphan drug designation to the Company’s CD34+ cell therapy product, CLBS12, for the treatment of Buerger’s disease